Status: Not yet recruiting
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Participants needed: 178
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Nerviano Medical Sciences (Shanghai) Ltd.Updated: Jan 28, 2026Locations: 1
Eligibility criteria
Subject must be ≥18 years of age. [+6]
Non-adenocarcinoma histology of NSCLC. Patients whose tumors have a mixed histol... [+5]